| __timestamp | Geron Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 570979 |
| Thursday, January 1, 2015 | 9574000 | 2185000 |
| Friday, January 1, 2016 | 14695000 | 4554000 |
| Sunday, January 1, 2017 | 8437000 | 3605000 |
| Monday, January 1, 2018 | 12723000 | 5527000 |
| Tuesday, January 1, 2019 | 51272000 | 5234000 |
| Wednesday, January 1, 2020 | 50052000 | 6126000 |
| Friday, January 1, 2021 | 783000 | 6784000 |
| Saturday, January 1, 2022 | 868000 | 7592000 |
| Sunday, January 1, 2023 | 123740000 | 11450000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating comparison of the cost of revenue between Geron Corporation and Travere Therapeutics, Inc. over the past decade.
From 2014 to 2023, Geron Corporation's cost of revenue has shown significant fluctuations, peaking in 2023 with a staggering 1,237% increase compared to 2014. This dramatic rise highlights the company's aggressive investment in research and development. In contrast, Travere Therapeutics, Inc. has maintained a more stable cost structure, with a modest 100% increase over the same period, reflecting a steady growth strategy.
The data reveals a compelling narrative of two companies navigating the biotech landscape with distinct approaches. As the industry continues to evolve, these insights offer valuable lessons on the impact of cost management on long-term success.
Cost Insights: Breaking Down Eli Lilly and Company and Travere Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Novo Nordisk A/S and Geron Corporation's Expenses
Cost of Revenue: Key Insights for AbbVie Inc. and Geron Corporation
Cost of Revenue: Key Insights for AstraZeneca PLC and Travere Therapeutics, Inc.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Geron Corporation's Expenses
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Geron Corporation
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Travere Therapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Geron Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Geron Corporation vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Geron Corporation and Wave Life Sciences Ltd.